The Top 3 Biotech Stocks That Could Race Higher in 2021

Biotech is still one of the most exciting sectors to invest in.

By 2025, the global biotech market could be worth up to $720 billion, according to Global Market Insights. In fact, they note:

“An increasing number of chronic diseases including cancer, heart disease, stroke, asthma, chronic respiratory diseases and hypertension among others will positively influence the biotechnology market growth. Unhealthy diet and lifestyle habits including alcohol consumption and tobacco are among the major reasons for the increase in the prevalence of chronic diseases. Therefore, the Department of Biotechnology through technical expert committee (TEC) and expert groups are focusing on R&D activities to develop innovative methods in cancer and neuro-disease biology. Hence, rising incidences of such chronic diseases, owing to several factors including stress and sedentary lifestyles, foster the overall business growth.”

Plus, there’s also incredible new innovation in genetics and technology.

Over the next several years, genetic testing and gene editing will help to identify and potentially cure diseases. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls.

With that in mind, here are three hot companies to pay close attention to.

**Intellia Therapeutics (NTLA)**

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.

Gene editing stocks are running on two key catalysts at the moment.

One, Ark Investment Management CEO Cathie Wood said, “I would have to say the biggest upside surprises are going to come from the genomic space. That’s because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease,” as quoted by The Motley Fool.

Two, another gene editing company, Editas Medicine just filed a request with the US FDA to begin a Phase 1/2 study of EDIT-301 for sickle cell disease, which could be a winner given the success of preclinical data.

**TG Therapeutics (TGTX)**

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.

The company just announced the completion of the rolling submission of a Biologics License Application (BLA) to the US FDA requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ (umbralisib), the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL).

The US FDA previously granted Fast Track designation to the combination of ublituximab and umbralisib (U2) for the treatment of adult patients with CLL and orphan drug designation for ublituximab in combination with umbralisib for the treatment of CLL.
Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, “The rapid completion of this BLA submission is a critical step forward in our mission to bring our first proprietary combination regimen to patients with both treatment naïve and relapsed or refractory chronic lymphocytic leukemia. The FDA has previously granted the U2 combination both fast track designation as well as orphan drug designation for patients with CLL and we look forward to continuing to work closely with the FDA with the goal of bringing this novel treatment regimen to patients as quickly as possible.”

Cassava Sciences Inc. (SAVA)

Cassava Sciences is a clinical stage biotechnology company that develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease.

“In Q1 2021 we announced that our lead drug candidate, simufilam, improved cognition scores in 50 patients with Alzheimer’s disease who completed at least 6 months of open-label treatment,” said Remi Barbier, President & CEO.

“In mid-2021, we look forward to announcing cognition scores in patients who’ll have completed at least 12 months of open-label treatment with simufilam. To our knowledge, no drug has stabilized, much less improved, cognition scores over 12 months in patients with Alzheimer’s disease. For this reason, I feel there is a sense of anticipation around the upcoming release of 12-month clinical data from our open-label study, as well as our plans to conduct a pivotal Phase 3 program with simufilam in the second half of 2021.”